Physician profile
Uchechi Dibia
NPI 1033995386
$1,285.86
in general payments reported to CMS, 2019-2025
15 companies · $82.06 in 2025
The $82.06 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $162 · 2024: $1,042 · 2025: $82.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $192.90 | 2023-2024 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.77 | 2023-2024 | Caplyta |
| Abbvie INC. | $168.63 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.32 | 2023-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $115.82 | 2024 | Spravato, Invega Sustenna |
| Lundbeck LLC | $111.59 | 2023-2024 | Rexulti |
| Medtronic, INC. | $82.06 | 2025 | Synchromedii |
| E.R. Squibb & Sons, L.L.C. | $74.33 | 2024 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $71.19 | 2024 | Austedo Xr |
| Neurocrine Biosciences, INC. | $43.00 | 2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $42.96 | 2024 | Fanapt |
| Harmony Biosciences LLC | $21.11 | 2024 | |
| Alkermes, INC. | $20.52 | 2024 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $15.94 | 2024 | Quviviq |
| Sage Therapeutics, LLC | $14.72 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uchechi Dibia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.